Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026)

Protalix BioTherapeutics has reported Current Assets for 17 years, with the latest figure at $92.2 million in Q2 2026.

• On a quarterly basis, Current Assets rose 40.83% year-over-year to $92.2 million in Q2 2026; TTM through Jun 2026 was $92.2 million, a 40.83% increase from a year earlier, with the FY2025 full-year figure at $66.7 million, up 10.98% from the prior year.
• Current Assets was $92.2 million for Q2 2026 at Protalix BioTherapeutics, up from $86.4 million in the prior quarter.
• The five-year high for Current Assets was $92.2 million in Q2 2026, with the low at $44.9 million in Q4 2022.
• Average Current Assets over 5 years is $64.8 million, with a median of $66.0 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Current Assets slumped 48.19% in 2022, then jumped 58.69% in 2023.
• Over 5 years, Current Assets stood at $44.9 million in 2022, then jumped by 55.82% to $69.9 million in 2023, then dropped by 14.09% to $60.1 million in 2024, then rose by 10.98% to $66.7 million in 2025, then surged by 38.32% to $92.2 million in 2026.
• The last three Current Assets figures came in at $92.2 million (Q2 2026), $86.4 million (Q1 2026), and $66.7 million (Q4 2025), per Business Quant data.